Cargando…
Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001047/ https://www.ncbi.nlm.nih.gov/pubmed/36900424 http://dx.doi.org/10.3390/cancers15051485 |
| _version_ | 1784904036683612160 |
|---|---|
| author | Wind, Selinde S. Jansen, Manon A. A. Rijsbergen, Melanie van Esdonk, Michiel J. Ziagkos, Dimitrios Cheng, Wing C. Niemeyer-van der Kolk, Tessa Korsten, John Gruszka, Agnieszka Schmitz-Rohmer, Debora Bonnel, David Legouffe, Raphael Barré, Florian Bekkenk, Marcel W. de Haas, Ellen R. M. Quint, Koen D. Schnidar, Harald Rolli, Melanie Streefkerk, Henk Johan Burggraaf, Jacobus Vermeer, Maarten H. Rissmann, Robert |
| author_facet | Wind, Selinde S. Jansen, Manon A. A. Rijsbergen, Melanie van Esdonk, Michiel J. Ziagkos, Dimitrios Cheng, Wing C. Niemeyer-van der Kolk, Tessa Korsten, John Gruszka, Agnieszka Schmitz-Rohmer, Debora Bonnel, David Legouffe, Raphael Barré, Florian Bekkenk, Marcel W. de Haas, Ellen R. M. Quint, Koen D. Schnidar, Harald Rolli, Melanie Streefkerk, Henk Johan Burggraaf, Jacobus Vermeer, Maarten H. Rissmann, Robert |
| author_sort | Wind, Selinde S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10001047 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100010472023-03-11 Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 Wind, Selinde S. Jansen, Manon A. A. Rijsbergen, Melanie van Esdonk, Michiel J. Ziagkos, Dimitrios Cheng, Wing C. Niemeyer-van der Kolk, Tessa Korsten, John Gruszka, Agnieszka Schmitz-Rohmer, Debora Bonnel, David Legouffe, Raphael Barré, Florian Bekkenk, Marcel W. de Haas, Ellen R. M. Quint, Koen D. Schnidar, Harald Rolli, Melanie Streefkerk, Henk Johan Burggraaf, Jacobus Vermeer, Maarten H. Rissmann, Robert Cancers (Basel) Correction MDPI 2023-02-27 /pmc/articles/PMC10001047/ /pubmed/36900424 http://dx.doi.org/10.3390/cancers15051485 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Correction Wind, Selinde S. Jansen, Manon A. A. Rijsbergen, Melanie van Esdonk, Michiel J. Ziagkos, Dimitrios Cheng, Wing C. Niemeyer-van der Kolk, Tessa Korsten, John Gruszka, Agnieszka Schmitz-Rohmer, Debora Bonnel, David Legouffe, Raphael Barré, Florian Bekkenk, Marcel W. de Haas, Ellen R. M. Quint, Koen D. Schnidar, Harald Rolli, Melanie Streefkerk, Henk Johan Burggraaf, Jacobus Vermeer, Maarten H. Rissmann, Robert Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title | Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title_full | Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title_fullStr | Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title_full_unstemmed | Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title_short | Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510 |
| title_sort | correction: wind et al. topical bimiralisib shows meaningful cutaneous drug levels in healthy volunteers and mycosis fungoides patients but no clinical activity in a first-in-human, randomized controlled trial. cancers 2022, 14, 1510 |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001047/ https://www.ncbi.nlm.nih.gov/pubmed/36900424 http://dx.doi.org/10.3390/cancers15051485 |
| work_keys_str_mv | AT windselindes correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT jansenmanonaa correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT rijsbergenmelanie correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT vanesdonkmichielj correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT ziagkosdimitrios correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT chengwingc correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT niemeyervanderkolktessa correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT korstenjohn correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT gruszkaagnieszka correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT schmitzrohmerdebora correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT bonneldavid correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT legoufferaphael correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT barreflorian correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT bekkenkmarcelw correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT dehaasellenrm correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT quintkoend correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT schnidarharald correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT rollimelanie correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT streefkerkhenkjohan correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT burggraafjacobus correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT vermeermaartenh correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 AT rissmannrobert correctionwindetaltopicalbimiralisibshowsmeaningfulcutaneousdruglevelsinhealthyvolunteersandmycosisfungoidespatientsbutnoclinicalactivityinafirstinhumanrandomizedcontrolledtrialcancers2022141510 |